Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. (Q54322737)
Jump to navigation
Jump to search
scientific article published on 13 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. |
scientific article published on 13 September 2014 |
Statements
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. (English)
1 reference
Claire Fabre
1 reference
Marco Gobbi
1 reference
Cyrine Ezzili
1 reference
Mustapha Zoubir
1 reference
Marie-Paule Sablin
1 reference
Karen Small
1 reference
Ellie Im
1 reference
Nabeegha Shinwari
1 reference
Da Zhang
1 reference
Honghong Zhou
1 reference
Christophe Le Tourneau
1 reference
13 September 2014
1 reference
74
1 reference
5
1 reference
1057-1064
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference